[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2025-11-26-5":3},{"date":4,"filings":5,"has_more":42,"limit":43,"page":44,"total_count":45},"2025-11-26",[6,14,21,28,35],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"Sun Pharmaceutical Industries Limited","2025-11-26T08:56:47.344000","NSE","FDA approves label update for UNLOXCYT™ based on improved clinical outcomes data","692673cbbd76f2655213e3fe","SUNPHARMA","• FDA has approved a label update for UNLOXCYT™ (cosibelimab-ipdl)\n• Update based on longer-term data showing improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)\n• Common adverse reactions (≥10%) include fatigue, musculoskeletal pain, rash, diarrhea, and hypothyroidism\n• Suspected adverse reactions can be reported to Sun Pharma's Drug Safety Department or the FDA",{"company_name":15,"filing_date":16,"filing_source":9,"headline":17,"id":18,"stock_code":19,"summary_text":20},"SMS Pharmaceuticals Limited","2025-11-26T08:26:45.063000","Corporate Filing Announcement","69266f06bd76f2655213e3fc","SMSPHARMA","• SMS Pharmaceuticals has submitted a filing to both BSE Limited and National Stock Exchange of India Ltd\n• The filing includes a press release with a standard disclaimer about forward-looking statements\n• The company notes that actual results may differ from those expressed or implied in the statements\n• Thirumalesh Tumma is identified as the Company Secretary handling the filing\n• Investor relations contacts are provided for further information",{"company_name":22,"filing_date":23,"filing_source":24,"headline":25,"id":26,"stock_code":19,"summary_text":27},"SMS Pharmaceuticals Ltd","2025-11-26T08:26:44.205000","BSE","Forward-Looking Statements Disclaimer","69266cbf31c7605140096bea","• Company issued a standard disclaimer regarding forward-looking statements\n• Statements are subject to economic changes, tax laws, inflation, and litigation risks\n• Actual results may differ from those expressed or implied\n• Company will not be responsible for actions taken based on these statements\n• No obligation to update forward-looking statements for subsequent events",{"company_name":29,"filing_date":30,"filing_source":9,"headline":31,"id":32,"stock_code":33,"summary_text":34},"TAC Infosec Limited","2025-11-26T07:01:44.316000","TAC InfoSec Limited Joins Nifty Emerge Index as the 5th Largest Company by Weight","692658dc1d544137076df237","TAC","• TAC InfoSec Limited (NSE: TAC) has secured a position in the Nifty SME Emerge Index\n• The company ranks as the 5th largest by weight in this prestigious index\n• TAC is recognized as the 5th largest Vulnerability Management company globally by client count\n• This milestone represents significant recognition in India's capital markets landscape\n• The announcement was made in compliance with Regulation 30 of LODR requirements",{"company_name":36,"filing_date":37,"filing_source":24,"headline":38,"id":39,"stock_code":40,"summary_text":41},"Bayer CropScience Ltd","2025-11-26T00:06:43.941000","Audio\u002FVideo Recording of Investor Meet Now Available","69260d4dbd76f2655213e3fa","BAYERCROP","• Company held an Investor Meet on November 25, 2025\n• Recording has been made available on the company website\n• Access available at: https:\u002F\u002Fwww.bayer.in\u002Fen\u002Finvestors\u002Finvestor-presentation\n• Disclosure made in compliance with SEBI Regulation 30\n• Follows previous communication dated November 18, 2025",false,100,5,405]